Biotech · Private company · Jupiter, FL, US
Myosin Therapeutics Inc.
Track this companyFree. Adds Myosin Therapeutics Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials22 recruiting or active
Pipeline programs2From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline2
- MT-125Phase 2 · GlioblastomaClinicalTrials.gov · fetched Nov 12, 2026
- MT-125Phase 2 · Glioblastoma (GBM)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated GlioblastomaPHASE1_PHASE2 · NOT_YET_RECRUITING · started Jul 1, 2026ClinicalTrials.gov NCT07604285 · fetched Nov 12, 2026
- A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM PatientsPHASE1_PHASE2 · RECRUITING · started Apr 1, 2026ClinicalTrials.gov NCT07185880 · fetched Nov 12, 2026
NIH awards6
- Phase 0/I dose escalation trial of MT-125 monotherapy in recurrent high-grade gliomasFiscal year 2026 · $2.2MNIH RePORTER 5R44CA278293-05 · fetched Nov 12, 2026
- Phase 0/1b Clinical Trial of Novel Therapeutic Agent MT-110 for the Reduction of Methamphetamine Use - Part 2Fiscal year 2025 · $1.5MNIH RePORTER 1R44DA063266-01 · fetched Nov 12, 2026
- Development of drug product to support a Phase 0/1b dose escalation trial of MT-125 in recurrent high grade gliomasFiscal year 2025 · $249.4KNIH RePORTER 1SB1CA302068-01 · fetched Nov 12, 2026
- Phase 0/I dose escalation trial of MT-125 monotherapy in recurrent high-grade gliomasFiscal year 2025 · $2.2MNIH RePORTER 2R44CA278293-04 · fetched Nov 12, 2026
- MT-125 for the Therapeutic Treatment of GlioblastomaFiscal year 2025 · $911.4KNIH RePORTER 5R42CA278293-03 · fetched Nov 12, 2026
- MT-125 for the Therapeutic Treatment of GlioblastomaFiscal year 2024 · $1.3MNIH RePORTER 4R42CA278293-02 · fetched Nov 12, 2026